Gilteritinib enhances anti-tumor ef fi cacy of cdk4/6 inhibitor, abemaciclib in lung cancer cells

HIGHLIGHTS

• who: CDK et al. from the College of Biological and Pharmaceutical Engineering, West Anhui University, Lu`an, China, Department of Physiology and have published the research work: Gilteritinib Enhances Anti-Tumor Ef fi cacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells, in the Journal: (JOURNAL)
• what: The authors investigated the antitumor effect of abemaciclib alone, or in combination with gilteritinib in lung cancer cells, and demonstrated that gilteritinib enhances the cytotoxicity of abemaciclib in_vitro and in_vivo.
• how: DESeq2 results were analyzed using a p and amplt 0.05 significance followed by . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.